Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews
Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews
揭秘intra-cellular therapies：從15篇分析師評論中得出的見解
An in-depth analysis of recent...In the last three months, 15 analysts have published ratings on Intra-Cellular Therapies (NASDAQ:ITCI), offering a diverse range of perspectives from bullish to bearish.
在過去三個月中，有15位分析師對納斯達克股票Intra-Cellular Therapies (NASDAQ:ITCI) 發佈了評級，提供了從看好到看淡的多樣化觀點。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他們最近的評級概況，突出了過去30天內情緒的變化，並將其與之前的月份進行了比較。
Analysts have set 12-month price targets for Intra-Cellular Therapies, revealing an average target of $100.93, a high estimate of $130.00, and a low estimate of $74.00. This current average has increased by 2.78% from the previous average price target of $98.20.
分析師們爲intra-cellular therapies設定了12個月的目標股價，平均目標爲100.93美元，高估爲130.00美元，低估爲74.00美元。當前的平均目標較上一個98.20美元的目標股價上漲了2.78%。
Investigating Analyst Ratings: An Elaborate Study
分析師評級的調查：一項詳盡的研究
An in-depth analysis of recent...
一項深入分析...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間